Ralph S. Shapiro

Hematology | Oncology

15700 37th Ave N Ste 110
Minneapolis, MN 55446

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Vulnerable newborn types: analysis of subnational, population-based birth cohorts for 541 285 live births in 23 countries, 2000-2021.

Vulnerable newborn types: analysis of subnational, population-based birth cohorts for 541 285 live births in 23 countries, 2000-2021.

Journal: BJOG : an international journal of obstetrics and gynaecology

Published: November 19, 2022

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.

Journal: Frontiers in immunology

Published: May 10, 2021

Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema.

Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema.

Journal: The journal of allergy and clinical immunology. In practice

Published: April 25, 2019

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.

Journal: JAMA

Published: November 28, 2018

An essential role for the Zn2+ transporter ZIP7 in B cell development.

An essential role for the Zn2+ transporter ZIP7 in B cell development.

Journal: Nature immunology

Published: February 04, 2018

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema.

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema.

Journal: Allergy & rhinology (Providence, R.I.)

Published: April 07, 2017

Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16).

Construction and validation of a novel disease-specific quality-of-life instrument for patients with primary antibody deficiency disease (PADQOL-16).

Journal: The Journal of allergy and clinical immunology

Published: July 28, 2016

Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.

Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: July 05, 2016

Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients.

Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients.

Journal: The journal of allergy and clinical immunology. In practice

Published: June 16, 2016

Facilitating home-based treatment of hereditary angioedema.

Facilitating home-based treatment of hereditary angioedema.

Journal: Allergy and asthma proceedings

Published: January 01, 2015

7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.

7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.

Journal: Clinical and experimental immunology

Published: December 30, 2014

7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.

7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.

Journal: Clinical and experimental immunology

Published: December 30, 2014

Showing 1-12 of 27

Last Updated: 09/26/2026